BG Medicine Posts 85 Percent Jump in Q1 Revenues, Appoints New CEO | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine today reported first quarter revenues of $888,000, up 85 percent from $480,000 in the first quarter of 2012.

The company also announced that it had appointed Paul Sohmer as president and CEO, replacing Eric Bouvier.

The revenue increase was driven by $820,000 in revenues from sales of the company's BGM Galectin-3 test, a 97 percent jump from the $416,000 it posted in Q1 2012. The remaining $68,000 in revenues came from BG's services business, up 6 percent from $64,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.